ITAM–Syk signaling mediates the rebound phenomenon after anti-RANKL antibody discontinuation
Bone · 2026
DOI: 10.1016/j.bone.2026.117776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2026. Verfasst von Hotaka Ishizu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ultrastructure of Hard Tissue, Graduate School of Dental Medicine, Faculty of Dental Medicine, Hokkaido University, Sapporo, Japan; Department of Ort…. Hauptthemen laut MEDLINE: Syk Kinase, Signal Transduction, RANK Ligand. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Japan Orthopaedics and Traumatology Foundation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Rebound bone loss following discontinuation of antiresorptive therapy, especially denosumab, represents a major clinical issue due to rapid osteoclast activation and increased fracture risk. However, the molecular basis of this phenomenon remains poorly understood. In this study, we investigated the role of the DAP12/TREM2-Syk signaling pathway in rebound-associated bone resorption using a murine model treated with and withdrawn from a RANKL-neutralizing antibody. Wild-type (WT) mice exhibited marked rebound bone loss, with elevated expression of DAP12/TREM2-related genes (Tyrobp and Trem2), increased infiltration of CD206+ M2 macrophages, and enhanced osteoclast formation. In contrast, DAP12/DAP10 double-knockout (DKO) mice showed diminished osteoclast activity, reduced M2 macrophage presence, and preserved bone mass, indicating the essential role of this signaling axis. Furthermore, pharmacological inhibition of Syk in WT mice effectively prevented rebound bone loss without disturbing normal bone turnover. Histological and ultrastructural analyses revealed hyperactive osteoclasts with enlarged ruffled borders in WT but not in DKO mice. These results identify the DAP12/TREM2-Syk pathway as a key regulator of pathological osteoclast activation after anti-RANKL therapy withdrawal, suggesting that its inhibition may provide a novel therapeutic approach to prevent rebound bone loss while maintaining physiological bone remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ultrastructure of Hard Tissue, Graduate School of Dental Medicine, Faculty of Dental Medicine, Hokkaido University, Sapporo, Japan; Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine,…
- Ultrastructure of Hard Tissue, Graduate School of Dental Medicine, Faculty of Dental Medicine, Hokkaido University, Sapporo, Japan. Electronic address: hasegawa@den.hokudai.ac.jp.
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Electronic address: simitom@wg8.so-net.ne.jp.
- Ultrastructure of Hard Tissue, Graduate School of Dental Medicine, Faculty of Dental Medicine, Hokkaido University, Sapporo, Japan.
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Förderung
- Japan Orthopaedics and Traumatology Foundation
- Japan Society for the Promotion of Science
Zitieren
APA
Ishizu, H., Hasegawa, T., Shimizu, T., Yamamoto, T., Asano, T., Iwasaki, N., & Amizuka, N. (2026). ITAM–Syk signaling mediates the rebound phenomenon after anti-RANKL antibody discontinuation. Bone. https://doi.org/10.1016/j.bone.2026.117776
Vancouver
Ishizu H, Hasegawa T, Shimizu T, Yamamoto T, Asano T, Iwasaki N, et al. ITAM–Syk signaling mediates the rebound phenomenon after anti-RANKL antibody discontinuation. Bone. 2026. doi:10.1016/j.bone.2026.117776
BibTeX
@article{Ishizu2026,
author = {Ishizu, Hotaka and Hasegawa, Tomoka and Shimizu, Tomohiro and Yamamoto, Tomomaya and Asano, Tsuyoshi and Iwasaki, Norimasa and Amizuka, Norio},
title = {ITAM–Syk signaling mediates the rebound phenomenon after anti-RANKL antibody discontinuation},
journal = {Bone},
year = {2026},
doi = {10.1016/j.bone.2026.117776}
}
EUVIMED